🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  2. Placebo to match LY, Mirikizumab, Placebo to Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  3. Placebo to match LY3540378

    Eli Lilly Co.

    Heart Failure with Preserved Ejection Fraction, Heart Failure

    phase 2 small molecule active

    1 trial

  4. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  5. Placebo to match LY3848575

    Eli Lilly Co.

    Neuropathic Pain; Distal Sensory Polyneuropathy

    phase 2 small molecule active

    1 trial

  6. Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension, Brimonidine Tartrate 0.2% w/v Eye Drops., Alphagan 2 mg/ml colirio en solución, IMGN151

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  7. Privigen 100 mg/ml solution for infusion, Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  8. Probiotics Compound (Biolosion)

    Sun Yat-sen University

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  9. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  10. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  11. Ramucirumab

    Eli Lilly and Company

    Gastric Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  12. Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose

    CanSino Biologics

    Poliomyelitis

    phase 2 mab active

    1 trial

  13. SBRT combined with Nimotuzumab followed by Tislelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  14. SBRT combined with Tislelizumab followed by Tislelizumab

    Zibo Municipal Hospital

    NSCLC

    phase 2 small molecule active

    1 trial

  15. SELINEXOR

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  16. SHR-A1921 injection and adebrelimab injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  17. SOLDESAM 0,2% gocce orali, soluzione, Pepaxti 20 mg powder for concentrate for solution for infusion, SOLDESAM 8 mg/2 ml soluzione iniettabile

    Fondazione Telethon ETS

    Relapsed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  18. STN1010904, Placebo (vehicle), STN1010904

    Santen Oy

    Fuchs Endothelial Corneal Dystrophy (FECD)

    phase 2 small molecule active

    1 trial

  19. Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    Takeda

    Poliomyelitis

    phase 2 mab terminated

    1 trial

  20. Sacituzumab Tirumotecan in combination with tislelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  21. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Endothelial Dysfunction

    phase 2 small molecule completed

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Glioblastoma Multiforme

    phase 2 small molecule terminated

    1 trial

  23. Selinexor

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule terminated

    1 trial

  24. Selinexor

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources